JP2012526852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526852A5 JP2012526852A5 JP2012511052A JP2012511052A JP2012526852A5 JP 2012526852 A5 JP2012526852 A5 JP 2012526852A5 JP 2012511052 A JP2012511052 A JP 2012511052A JP 2012511052 A JP2012511052 A JP 2012511052A JP 2012526852 A5 JP2012526852 A5 JP 2012526852A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- genotype
- promoter gene
- agent
- result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 39
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 13
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 13
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims 13
- 108700028369 Alleles Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 8
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 8
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 4
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 4
- 229960000894 sulindac Drugs 0.000 claims 4
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical group NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 4
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 3
- 208000003200 Adenoma Diseases 0.000 claims 2
- 208000004804 Adenomatous Polyps Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 108020002494 acetyltransferase Proteins 0.000 claims 2
- 102000005421 acetyltransferase Human genes 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 229940063673 spermidine Drugs 0.000 claims 2
- 229940063675 spermine Drugs 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21621609P | 2009-05-14 | 2009-05-14 | |
| US61/216,216 | 2009-05-14 | ||
| US21768209P | 2009-06-03 | 2009-06-03 | |
| US21767909P | 2009-06-03 | 2009-06-03 | |
| US61/217,682 | 2009-06-03 | ||
| US61/217,679 | 2009-06-03 | ||
| PCT/US2010/034974 WO2010132817A1 (en) | 2009-05-14 | 2010-05-14 | Carcinoma diagnosis and treatments, based on odc1 genotype |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015213116A Division JP2016074672A (ja) | 2009-05-14 | 2015-10-29 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526852A JP2012526852A (ja) | 2012-11-01 |
| JP2012526852A5 true JP2012526852A5 (cg-RX-API-DMAC7.html) | 2013-06-27 |
| JP6083860B2 JP6083860B2 (ja) | 2017-02-22 |
Family
ID=43085356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511052A Expired - Fee Related JP6083860B2 (ja) | 2009-05-14 | 2010-05-14 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
| JP2015213116A Pending JP2016074672A (ja) | 2009-05-14 | 2015-10-29 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015213116A Pending JP2016074672A (ja) | 2009-05-14 | 2015-10-29 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8329636B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2430452B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6083860B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102483415B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010248803B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2761946A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2430452T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2507145T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20140887T1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL216369B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2430452T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2430452E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2430452T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT201400177B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010132817A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2761946A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California, A California Corporation | Carcinoma diagnosis and treatment, based on odc1 genotype |
| JP6083646B2 (ja) * | 2010-05-14 | 2017-02-22 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| US20120172244A1 (en) | 2010-12-20 | 2012-07-05 | Steven Buechler | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
| EP2655663A4 (en) * | 2010-12-20 | 2015-01-28 | Univ Notre Dame Du Lac | BIOMARKERS AND THEIR USE FOR PROGNOSIS AND TREATMENT STRATEGIES FOR RIGHT-SIDED AND LEFT-SIDE COLON CARCINOMA |
| HUE040263T2 (hu) | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
| CA2952771A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| WO2016130918A1 (en) * | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
| CN107750279A (zh) * | 2015-03-16 | 2018-03-02 | 个人基因组诊断公司 | 核酸分析系统和方法 |
| MX390899B (es) | 2015-10-30 | 2025-03-21 | Cancer Prevention Pharmaceuticals Inc | Formulación de combinación de dosis fija, eflornitina y sulindaco. |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| JP6963271B2 (ja) * | 2017-01-20 | 2021-11-05 | 国立大学法人東海国立大学機構 | イヌの遺伝性消化管腫瘍症の遺伝子診断法 |
| US10945981B2 (en) | 2019-05-17 | 2021-03-16 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| IL63907A0 (en) | 1980-09-24 | 1981-12-31 | Cetus Corp | Diagnostic method and antibody probe for use therein |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| EP0754240B1 (en) | 1994-02-07 | 2003-08-20 | Beckman Coulter, Inc. | Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| WO1999049859A1 (en) * | 1998-03-28 | 1999-10-07 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Dfmo and sulindac combination in cancer chemoprevention |
| US7700568B2 (en) * | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
| AU783992B2 (en) * | 1998-12-23 | 2006-01-12 | G.D. Searle Llc | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| CA2373931A1 (en) | 1999-05-17 | 2000-11-23 | Richard Love | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| EP1351675A2 (en) | 2000-08-24 | 2003-10-15 | The Regents of the University of California | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| US7273888B2 (en) | 2001-11-16 | 2007-09-25 | Als Therapy Development Foundation, Inc. | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis |
| WO2007075673A1 (en) | 2005-12-20 | 2007-07-05 | University Of Hawaii | Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors |
| US8283331B2 (en) | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| ES2639444T3 (es) | 2008-12-08 | 2017-10-26 | The Procter & Gamble Company | Composición para la higiene personal en forma de un artículo que tiene un recubrimiento hidrófobo que reside en la superficie |
| CA2761946A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California, A California Corporation | Carcinoma diagnosis and treatment, based on odc1 genotype |
| JP6083646B2 (ja) | 2010-05-14 | 2017-02-22 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| HUE040263T2 (hu) | 2012-10-29 | 2019-02-28 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | Prediktív markerek poliamin-inhibitor rákterápiákhoz |
-
2010
- 2010-05-14 CA CA2761946A patent/CA2761946A1/en not_active Abandoned
- 2010-05-14 PT PT107756264T patent/PT2430452E/pt unknown
- 2010-05-14 DK DK10775626.4T patent/DK2430452T3/da active
- 2010-05-14 WO PCT/US2010/034974 patent/WO2010132817A1/en not_active Ceased
- 2010-05-14 US US12/780,592 patent/US8329636B2/en active Active
- 2010-05-14 SI SI201030738T patent/SI2430452T1/sl unknown
- 2010-05-14 AU AU2010248803A patent/AU2010248803B2/en not_active Ceased
- 2010-05-14 EP EP10775626.4A patent/EP2430452B1/en active Active
- 2010-05-14 JP JP2012511052A patent/JP6083860B2/ja not_active Expired - Fee Related
- 2010-05-14 CN CN201080031983.5A patent/CN102483415B/zh not_active Expired - Fee Related
- 2010-05-14 HR HRP20140887AT patent/HRP20140887T1/hr unknown
- 2010-05-14 PL PL10775626T patent/PL2430452T3/pl unknown
- 2010-05-14 ES ES10775626.4T patent/ES2507145T3/es active Active
-
2011
- 2011-11-14 IL IL216369A patent/IL216369B/en active IP Right Grant
-
2012
- 2012-12-10 US US13/709,753 patent/US9121852B2/en active Active
-
2014
- 2014-11-21 SM SM201400177T patent/SMT201400177B/xx unknown
-
2015
- 2015-09-01 US US14/841,750 patent/US9937141B2/en active Active
- 2015-10-29 JP JP2015213116A patent/JP2016074672A/ja active Pending
-
2018
- 2018-02-23 US US15/904,153 patent/US20190038584A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526852A5 (cg-RX-API-DMAC7.html) | ||
| Tan et al. | Optimizing pain management to facilitate enhanced recovery after surgery pathways | |
| Sim et al. | Prospective randomized, double‐blind, placebo‐controlled study of pre‐and postoperative administration of a COX‐2‐specific inhibitor as opioid‐sparing analgesia in major colorectal surgery | |
| van der Heijde et al. | Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty‐two–week, randomized, controlled study | |
| Moller et al. | Onset of acetaminophen analgesia: comparison of oral and intravenous routes after third molar surgery | |
| Young et al. | Recent advances in multimodal analgesia | |
| Mercadante et al. | Pharmacological management of cancer pain in the elderly | |
| Joffe et al. | Evaluation and treatment of pain in critically ill adults | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| Lotia et al. | New and emerging medical therapies in Parkinson’s disease | |
| Minkowitz et al. | Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: A randomized, placebo‐controlled, phase‐3 study | |
| Viscusi et al. | Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability | |
| Stasiowska et al. | Postoperative pain management | |
| Richardson et al. | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma | |
| JP2018507910A5 (cg-RX-API-DMAC7.html) | ||
| Daniels et al. | Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| Christensen et al. | A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain | |
| Douzjian et al. | Old drug, new route: a systematic review of intravenous acetaminophen after adult cardiac surgery | |
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib | |
| Seeberger et al. | Carbidopa levodopa enteral suspension | |
| Nishimoto | OFIRMEV: an old drug becomes new again | |
| Bodnar | The use of propofol for continuous deep sedation at the end of life: a definitive guide | |
| Al Dakheel et al. | Emerging drugs for levodopa-induced dyskinesia |